Open access
Open access
Powered by Google Translator Translator

Vaccines

Cohort study: Pfizer vaccine effectiveness against any infections declined from 88% during the first month after full vaccination to 47% after 5 months. Vaccine effectiveness against hospital admissions remained high; 87% within 1 month, and 88% at 5 months after full vaccination, with no significant waning.

5 Oct, 2021 | 10:09h | UTC

Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study – The Lancet

Commentary: Expert reaction to study on Pfizer-BioNTech vaccine effectiveness up to 6 months – Science Media Centre

 

Commentary on Twitter

 

New analysis shows benefits of offering two doses of COVID-19 vaccine to children aged 12-17 clearly outweigh risks.

3 Oct, 2021 | 22:52h | UTC

News release: New analysis shows benefits of offering two doses of COVID-19 vaccine to children aged 12-17 clearly outweigh risks – The Royal Society of Medicine

Original report: Vaccinating adolescents against SARS-CoV-2 in England: a risk-benefit analysis

Related: Covid: Single jab recommended for 12 to 15-year-olds by UK’s top doctors.

 

Editorial | Clinical ethics: consent for vaccination in children.

3 Oct, 2021 | 22:53h | UTC

Clinical ethics: consent for vaccination in children – Archives of Disease in Childhood

 

Randomized trial with over 30.000 patients showed AstraZeneca vaccine was safe and resulted in 74% efficacy against symptomatic SARS-CoV-2 infection.

30 Sep, 2021 | 10:32h | UTC

Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine – New England Journal of Medicine

 

Commentaries on Twitter

https://twitter.com/NEJM/status/1443331005050355715

https://twitter.com/EricTopol/status/1443336261897392133

 

[Preprint] More data showing longer dosing interval increases immune response after Pfizer-BioNTech’s COVID-19 vaccine.

26 Sep, 2021 | 22:15h | UTC

Strong humoral immune responses against SARS-CoV-2 Spike after BNT162b2 mRNA vaccination with a sixteen-week interval between doses – medRxiv

Commentary: Researchers encourage longer dosing intervals for Pfizer-BioNTech’s COVID-19 vaccine – News Medical

Related:

[Preprint] Covid-19: Longer interval between Covid-19 Pfizer vaccine doses boosts immunity.

[Preprint] Delaying second Pfizer vaccine dose to 12 weeks increases specific antibody response 3.5-fold in people over 80 years of age.

Study Commentary | Single-dose Oxford–AstraZeneca COVID-19 vaccine followed by a 12-week booster

3-month interval between first and second dose of Oxford COVID-19 vaccine results in higher vaccine efficacy than 6-week interval

 

In Gratitude for mRNA Vaccines.

26 Sep, 2021 | 22:13h | UTC

In Gratitude for mRNA Vaccines – New England Journal of Medicine

 

Opinion | Inappropriate Mixing Clinical and Systemic Thinking: Vaccines in the Young.

26 Sep, 2021 | 22:07h | UTC

Inappropriate Mixing Clinical and Systemic Thinking: Vaccines in the Young – Medium

 

No, vaccinated people are not ‘just as likely’ to spread the Coronavirus as unvaccinated people.

24 Sep, 2021 | 10:06h | UTC

No, Vaccinated People Are Not ‘Just as Likely’ to Spread the Coronavirus as Unvaccinated People – The Atlantic

 

Commentary on Twitter

 

COVID-19 vaccines: Keeping pace with SARS-CoV-2 variants.

24 Sep, 2021 | 10:02h | UTC

COVID-19 vaccines: Keeping pace with SARS-CoV-2 variants – Cell

 

Commentary on Twitter

https://twitter.com/Sri_Baqri/status/1438865999281983490

 

[Preprint] Third dose of Sinopharm inactivated SARS-CoV-2 vaccine induces robust B and T cell responses.

23 Sep, 2021 | 10:18h | UTC

Robust induction of B cell and T cell responses by a third dose of inactivated SARS-CoV-2 vaccine – medRxiv

Commentaries:

Three doses of inactivated BBIBP-CorV SARS-CoV-2 vaccine induce robust B and T cell responses – News Medical

Sinopharm’s COVID booster reverses antibody decline, enhances cell-based responses – study – Reuters

 

Randomized phase 1/2 trial: Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in children and adolescents aged 3–17 years.

23 Sep, 2021 | 10:16h | UTC

Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial – The Lancet Infectious Diseases

Related: Phase 1/2 RCT: CoronaVac is well tolerated and safe and induces strong humoral responses in children and adolescents aged 3–17 years.

 

‘Not a zero-sum game’: Sharing vaccines is in countries’ best interests.

23 Sep, 2021 | 10:09h | UTC

‘Not a zero-sum game’: Sharing vaccines is in countries’ best interests – YaleNews

Original article: National interest may require distributing COVID-19 vaccines to other countries – Scientific Reports

 

Commentary on Twitter

 

[Press release – not published yet] J&J says booster shot at two months provided 75% protection against moderate to severe COVID-19 globally and 94% of such cases in the U.S.

22 Sep, 2021 | 10:26h | UTC

Press release: Johnson & Johnson Announces Real-World Evidence and Phase 3 Data Confirming Strong and Long-Lasting Protection of Single-Shot COVID-19 Vaccine in the U.S.

Commentaries:

Johnson & Johnson says additional dose boosts Covid vaccine efficacy – STAT

J&J booster 94% effective against severe COVID, company says – CIDRAP

Two dose version of Johnson & Johnson shot 94% effective against Covid-19, study finds – CNN

 

Commentaries on Twitter

(thread – click for more)

(thread – click for more)

https://twitter.com/hildabast/status/1440363761299124229

 

The fight to manufacture COVID vaccines in lower-income countries.

22 Sep, 2021 | 10:21h | UTC

The fight to manufacture COVID vaccines in lower-income countries – Nature

 

[Press release – not published yet] Pfizer announces COVID-19 vaccine in children 5 to 11 years produced strong neutralizing antibody responses.

21 Sep, 2021 | 09:57h | UTC

Pfizer and BioNTech Announce Positive Topline Results From Pivotal Trial of COVID-19 Vaccine in Children 5 to 11 Years – Pfizer and BioNTech

Commentaries:

Covid-19 vaccine for 5- to 11-year-olds is safe and shows ‘robust’ antibody response, Pfizer says – CNN

Pfizer says COVID-19 vaccine safe, effective in younger children – CIDRAP

Pfizer Covid-19 vaccine generates robust antibody response in children, without serious safety issues, company says – STAT

Expert reaction to press release giving topline results from Pfizer and BioNTech from their phase 2/3 trial looking at safety and antibody responses from their COVID-19 vaccine in children aged 5 to 11 – Science Media Centre

 

Commentaries on Twitter

(thread – click for more)

(thread – click for more)

https://twitter.com/hildabast/status/1439976038964940803

 

Uncoupling vaccination from politics: a call to action.

21 Sep, 2021 | 09:56h | UTC

Uncoupling vaccination from politics: a call to action – The Lancet

 

CDC Report: Moderna’s vaccine associated with greater effectiveness (93%) against Covid-19 hospitalization compared to Pfizer (88%) and J&J (71%) vaccines.

19 Sep, 2021 | 23:48h | UTC

Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions — United States, March–August 2021 – CDC Morbidity and Mortality Weekly Report

Commentaries:

Moderna’s vaccine is the most effective, but Pfizer and J&J also protect well, CDC-led study says – CNN

CDC: Moderna COVID vaccine most protective against hospital cases – CIDRAP

CDC data: Moderna vaccine has edge in preventing COVID-19 hospitalizations – UPI

 

Commentary on Twitter

 

An FDA panel says only high-risk Americans and those 65+ should get covid boosters.

19 Sep, 2021 | 23:45h | UTC

An FDA Panel Says Only High-Risk Americans And Those 65+ Should Get COVID Boosters – NPR

See also:

FDA advisory panel recommends booster doses of Covid-19 vaccine only for older and high-risk Americans – STAT

5 reasons why FDA advisers did not recommend Covid-19 booster shots for everyone – CNN

Top doctors say not so fast to Biden’s boosters-for-all plan – Associated Press

Related:

An observational study in Israel suggests additional protection from a 3rd dose of the Pfizer vaccine in individuals 60 years of age or older.

Third shot: UK to offer COVID booster jabs to over 50s.

COVID-19 vaccine efficacy does not support boosters for general population, review concludes.

COVID vaccine effects wane over time but still prevent death and severe illness.

What’s the evidence for COVID-19 booster shots?

WHO appeals for countries to postpone COVID-19 vaccine boosters until 2022 to prioritize vaccinating the most at-risk people around the world who are yet to receive their first dose.

AstraZeneca bosses warn against rush for boosters – “giving the most vulnerable, who may not have built up a full immune response from the first two, a third, top-up dose is “sensible”. But any decision to give a third, booster jab “to large swathes of the population”, to extend their protection from the first two, must be based on clinical data”.

 

Opinion | Vaccinate the World before Starting COVID Booster Shots – “Fewer than 0.5 percent of vaccine doses have been distributed to people living in low-income countries”.

19 Sep, 2021 | 23:41h | UTC

Vaccinate the World before Starting COVID Booster Shots – Scientific American

Related: WHO appeals for countries to postpone COVID-19 vaccine boosters until 2022 to prioritize vaccinating the most at-risk people around the world who are yet to receive their first dose.

 

Case series: Vaccine-induced thrombocytopenia with severe headache may precede cerebral venous sinus thrombosis by several days – patients with severe headache 5 to 20 days after adenovirus vector vaccination against Covid-19 should undergo immediate testing for thrombocytopenia and d-dimer levels and, if available, testing for anti–PF4–heparin IgG antibodies.

16 Sep, 2021 | 10:14h | UTC

Vaccine-Induced Thrombocytopenia with Severe Headache – New England Journal of Medicine

 

Commentary on Twitter

 

Third shot: UK to offer COVID booster jabs to over 50s.

16 Sep, 2021 | 10:11h | UTC

Third shot: UK to offer COVID booster jabs to over 50s – Associated Press

 

COVID vaccine effects wane over time but still prevent death and severe illness.

16 Sep, 2021 | 10:10h | UTC

COVID vaccine effects wane over time but still prevent death and severe illness – The Conversation

Related:

Perspective | What we actually know about waning immunity.

Another study shows Pfizer mRNA vaccine immunity is reduced over time.

[Press release – not published yet] Study shows vaccine protection wanes over time, but vaccines still offer good protection against severe disease.

Studies: COVID vaccine protection waning against infection but not hospitalization.

Pfizer says it’s time for a Covid booster; FDA and CDC say not so fast.

 

An observational study in Israel suggests additional protection from a 3rd dose of the Pfizer vaccine in individuals 60 years of age or older.

16 Sep, 2021 | 10:13h | UTC

Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel – New England Journal of Medicine

 

Review | Prevention of host-to-host transmission by SARS-CoV-2 vaccines.

15 Sep, 2021 | 09:16h | UTC

Prevention of host-to-host transmission by SARS-CoV-2 vaccines – The Lancet Infectious Diseases

Related:

Study ties COVID vaccines to lower transmission rates.

Effect of Vaccination on Household Transmission of SARS-CoV-2 in England – “the likelihood of household transmission was approximately 40 to 50% lower in households of index patients who had been vaccinated 21 days or more before testing positive than in households of unvaccinated index patients”.

Study in England showed one dose of COVID-19 vaccine can cut household transmission by up to half – This protection is on top of the reduced risk of a vaccinated person developing symptomatic infection, which is around 60 to 65% after the first dose

Covid-19 vaccination prevents transmission from vaccinated to unvaccinated household members.

 

CDC report finds unvaccinated people are 11 times more likely to die of COVID-19.

15 Sep, 2021 | 09:09h | UTC

Unvaccinated People Are 11 Times More Likely To Die Of COVID-19, New Research Finds – NPR

Original study: Monitoring Incidence of COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Status — 13 U.S. Jurisdictions, April 4–July 17, 2021 – CDC Morbidity and Mortality Weekly Report

 

Commentary on Twitter

 

Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.